Evidence map›Paper›PMID 38543301›Full record

ReviewPharmaceutics2024

Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems.

Suvankar Ghorai, Harshita Shand, Soumendu Patra, Kingshuk Panda, Maria J Santiago, Md Sohanur Rahman, Srinivasan Chinnapaiyan, Hoshang J Unwalla

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Treatment of lung diseasesMaterials today. Bio · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Suvankar GhoraiDepartment of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.
Harshita ShandDepartment of Microbiology, Raiganj University, Raiganj 733134, India.
Soumendu PatraDepartment of Microbiology, Raiganj University, Raiganj 733134, India.ORCID 0000-0001-7699-8119
Kingshuk PandaDepartment of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.
Maria J SantiagoDepartment of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.
Md Sohanur RahmanDepartment of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.ORCID 0000-0002-1133-268X
Srinivasan ChinnapaiyanDepartment of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.ORCID 0000-0001-5633-9749
Hoshang J UnwallaDepartment of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.
Florida International University · USRaiganj University · IN

Funding

Mechanisms of Defective Mitophagy and cellular Senescence in HIV-associated COPDR01HL147715 · NHLBI · FLORIDA INTERNATIONAL UNIVERSITY · PI IRFAN RAHMAN, HOSHANG JEHANGIR UNWALLA · 2019 to 2026
$2.6M
Aberrant Micro-managing of the Airway Epithelial Transcriptome in HIV-associated COPDR01HL167655 · NHLBI · FLORIDA INTERNATIONAL UNIVERSITY · PI IRFAN RAHMAN, HOSHANG JEHANGIR UNWALLA · 2023 to 2026
$2.6M
Resetting the Clock in HIV associated COPDR01HL158316 · NHLBI · FLORIDA INTERNATIONAL UNIVERSITY · PI RAHMAN, IRFAN, UNWALLA, HOSHANG JEHANGIR · 2022 to 2025
$2.1M
Transdisciplinary Training in Biomolecular and Biomedical SciencesT32GM132054 · NIGMS · FLORIDA INTERNATIONAL UNIVERSITY · PI DEGENNARO, MATTHEW, TSE-DINH, YUK-CHING · 2019 to 2023
$1.6M
A CRISP(e)R way to silence HIVR01AI174269 · NIAID · FLORIDA INTERNATIONAL UNIVERSITY · PI HOSHANG JEHANGIR UNWALLA · 2024 to 2026
$1.1M
NHLBI NIH HHS R01 HL147715NHLBI NIH HHS R01 HL158316NHLBI NIH HHS R01 HL167655NIAID NIH HHS R01 AI174269NIGMS NIH HHS T32 GM132054NIH HHS HL147715, HL158316, HL167655NIH HHS HU1R01AI174269
6 · The paper itself

Abstract

The continuous evolution of new viruses poses a danger to world health. Rampant outbreaks may advance to pandemic level, often straining financial and medical resources to breaking point. While vaccination remains the gold standard to prevent viral illnesses, these are mostly prophylactic and offer minimal assistance to those who have already developed viral illnesses. Moreover, the timeline to vaccine development and testing can be extensive, leading to a lapse in controlling the spread of viral infection during pandemics. Antiviral therapeutics can provide a temporary fix to tide over the time lag when vaccines are not available during the commencement of a disease outburst. At times, these medications can have negative side effects that outweigh the benefits, and they are not always effective against newly emerging virus strains. Several limitations with conventional antiviral therapies may be addressed by nanotechnology. By using nano delivery vehicles, for instance, the pharmacokinetic profile of antiviral medications can be significantly improved while decreasing systemic toxicity. The virucidal or virus-neutralizing qualities of other special nanomaterials can be exploited. This review focuses on the recent advancements in nanomedicine against RNA viruses, including nano-vaccines and nano-herbal therapeutics.

Indexed as

HIV/AIDSnano-herbalnanomedicinenano vaccineRNA virus

Identifiers

PMID38543301
PMCPMC10975899
OpenAlexW4392897201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.